One2Treat

Big news at One2Treat!   We’re proud to share that Emilie Barré has been promoted to Head of Solution Value.   In this new role, Emilie will be leading the charge in ensuring our software solutions and strategic services align with both our company mission and customers’ needs. Her passion for patient-centered drug development and team growth makes her a perfect fit for this role.   And that’s not all! Emilie was also recently featured in Outsourcing-Pharma, where she shared her inspiring journey—from a deep curiosity for science to making a real impact in clinical trials. Her story is a testament to perseverance, innovation, and the power of believing in your dreams.   Check out the full feature here 👉 https://lnkd.in/etAez_Rm   Congratulations, Emilie! We’re lucky to have you leading the way. 🚀    #ClinicalTrials #PatientFocused #WomenInScience

Transforming research through patient-centric design and innovation.   We’re excited to share that our article, co-authored by Tom Mann and Samuel Salvaggio, PhD, has been featured in Outsourcing-Pharma! 📰   The piece highlights: 👉 Patient-Centricity: Embedding patient perspectives into trial design to align treatments with real-world needs. 👉 Innovative Methods: Using multi-dimensional assessments like 𝐍𝐞𝐭 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐁𝐞𝐧𝐞𝐟𝐢𝐭 to improve decision-making and efficiency. 👉 Regulatory Trends: The impact of initiatives like the FDA’s Project Optimus and how the 𝐍𝐞𝐭 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐁𝐞𝐧𝐞𝐟𝐢𝐭 can help in dose selection.   Read the full article here 👉 https://lnkd.in/eguCj79t   #ClinicalTrials #patientfocused #Pharma

One2Treat Founder Marc Buyse is speaking today at the Cancéropôle Grand Sud-Ouest Club SMAC event in Bordeaux.   During this 1.5-day workshop, participants will address statistical concepts for sample size estimation in clinical research, in the context of innovative trial designs and non-standard primary endpoints.   Marc’s presentation highlights the 𝐍𝐞𝐭 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐁𝐞𝐧𝐞𝐟𝐢𝐭 estimator, a powerful approach that can reduce sample sizes by incorporating multiple prioritized patient-relevant outcomes into a single endpoint.   We’re proud to contribute to this important conversation about advancing clinical research methodologies.    Merci to Carine Bellera and Virginie Rondeau for the organization 🙏

Pleased to share an interview conducted by MediMix during the San Antonio Breast Cancer Symposium 2024, where we presented our work on HER2-positive early breast cancer in collaboration with TRIO - Translational Research in Oncology. In this interview, Marc Buyse, and Samuel Salvaggio, PhD discuss the benefit/risk balance of TCH vs. AC-TH, using BCIRG006 data analyzed with an innovative statistical methodology. The findings highlight TCH’s notable cardiac safety advantage and further support the transition away from anthracyclines. A special thank you to Francois Duhoux for expertly guiding the conversation and to MediMix for the opportunity to share these impactful insights. Discover more in MediMix’s post below.👇 #SABCS2024 #BreastCancer #Innovation

𝐖𝐡𝐚𝐭 𝐢𝐟 𝐰𝐞 𝐜𝐨𝐮𝐥𝐝 𝐜𝐡𝐚𝐧𝐠𝐞 𝐭𝐡𝐞 𝐰𝐚𝐲 𝐰𝐞 𝐞𝐬𝐭𝐢𝐦𝐚𝐭𝐞 𝐭𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐞𝐟𝐟𝐞𝐜𝐭𝐬 𝐢𝐧 𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐭𝐫𝐢𝐚𝐥𝐬?    🎥 Discover our latest video, highlighting the 𝐍𝐞𝐭 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐁𝐞𝐧𝐞𝐟𝐢𝐭 (𝐍𝐓𝐁)—a transformative methodology that is paving the way for more informed, patient-focused decision-making in healthcare and drug development.   The NTB prioritizes multiple clinically relevant outcomes into a single, comprehensive assessment, offering a holistic view of treatment impact and addressing the complexity of patient-centered care.   Watch the video to learn how NTB is revolutionizing clinical trials 👉   #NetTreatmentBenefit #ClinicalTrials #Patientfocuseddrugdevelopment 

Fantastic visit to the Institute Bordet this week as our experts, Rudradev Sengupta and Jean-Christophe Chiêm, PhD, met with the CTC statistics team Marianne Paesmans, Paulus Kristanto, Lieveke Ameye, Mélina HOUINSOU HANS alongside Francesco Sclafani.   This meeting provided an excellent opportunity to discuss how clinical trials can benefit from 𝐦𝐮𝐥𝐭𝐢-𝐝𝐢𝐦𝐞𝐧𝐬𝐢𝐨𝐧𝐚𝐥 𝐞𝐧𝐝𝐩𝐨𝐢𝐧𝐭𝐬. Incorporating outcomes that matter most to patients, the 𝐍𝐞𝐭 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐁𝐞𝐧𝐞𝐟𝐢𝐭 approach delivers insights to guide better, patient-focused decisions.   We also reviewed the ongoing #SHAPERS trial, which we collaboratively designed to evaluate the reduction of short-course radiotherapy for elderly rectal cancer patients. These inspiring discussions fuel our vision of a near future where patients play a pivotal role in influencing treatment decisions, ultimately optimizing their own health outcomes. For more info on the Net Treatment Benefit 👉 https://lnkd.in/dj8PbQGG

We’re excited to share that One2Treat colleagues Sébastien Coppe, PhD and Samuel Salvaggio, PhD will attend the #SCOPE2025 Summit in Orlando, Florida, from February 3–6, 2025.   Alongside the main event we are also sponsors of SCOPE Summit’s Clinical Trial Venture, Innovation & Partnering Conference.   Sebastien will take the stage in a panel discussion on how innovative companies are leveraging breakthrough technologies transform and advance healthcare.   Excited to be on stage with Angela Holmes, MSBME of OmniScience, Trân Lê of Grove AI, Kalyan Obalampalli (KO) of ClinAI Paresh Shah of CliniLink Health and Shwen Gwee of Health Disruptors Inc.   🌴 See you in Orlando!   For more info on SCOPE 👉 https://lnkd.in/g9N7SgA   And on the partnership event 👉 https://lnkd.in/eXUYpd-Y   #clinicaltrials #SCOPEsummit #HealthcareTransformation

Clinical Research News features One2Treat CEO, Sébastien Coppe, PhD, with another bold prediction for 2025!   Sébastien shares how 𝐩𝐫𝐢𝐨𝐫𝐢𝐭𝐢𝐳𝐢𝐧𝐠 𝐩𝐚𝐭𝐢𝐞𝐧𝐭𝐬’ 𝐯𝐨𝐢𝐜𝐞𝐬 𝐰𝐢𝐥𝐥 𝐫𝐞𝐝𝐞𝐟𝐢𝐧𝐞 𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐭𝐫𝐢𝐚𝐥𝐬.   By using tools to integrate patient perspectives early, invaluable insights into their needs, preferences, and lived experiences are gained, which in turn help define more relevant endpoints and ultimately improve the perceived value of the treatment.    This can lead to more convincing trial designs, successful approvals, and faster time to market.    This approach will become the gold standard, driving a more patient-focused, effective drug development process. Read the full article here 👉 https://lnkd.in/emJ8rwhx   #ClinicalResearch #2025Predictions #PatientCentricity 

🌟 𝐖𝐡𝐚𝐭 𝐋𝐢𝐞𝐬 𝐀𝐡𝐞𝐚𝐝 𝐟𝐨𝐫 𝐏𝐡𝐚𝐫𝐦𝐚 𝐢𝐧 𝟐𝟎𝟐𝟓? 🌟   In this PM360 Magazine piece predicting what’s next for the industry, Sébastien Coppe, PhD, One2Treat CEO, shares how regulatory evolution will be key to advancing patient-focused innovation.   Leveraging tools to incorporate patient perspectives early in trial design can revolutionize treatment assessment by enabling multidimensional endpoints. This ensures a comprehensive understanding of treatment impact, aligned with real-world needs.   Read all the predictions 👉 https://lnkd.in/gcN3AC8J #Innovation #2025Predictions #PatientCentricity 

🎄✨ Happy Holidays from One2Treat! ✨🎄   Thank you for being part of our journey this year. As we celebrate the season, we’re excited to continue driving change and delivering impactful solutions for a better, more patient-focused biopharma industry in 2025 and beyond.   Wishing you a joyful holiday season and a 2024 filled with health, happiness, and success, from all of us at One2Treat: Sébastien Coppe, PhD, Emilie Barré, Hatem Alharazin, Jean-Christophe Chiêm, PhD, Samuel Salvaggio, PhD, Benoit David, Mathilde Tournay, Sarah Kosta, Rudradev Sengupta, Tom Mann, Marc Buyse, Pascal Piedbois.